Isentress Hd

post-exposure prophylaxis for occupational exposure to HIV therapy, HIV
Treatment
1 FDA approval
20 Active Studies for Isentress Hd

What is Isentress Hd

RaltegravirThe Generic name of this drug
Treatment SummaryRaltegravir is a medication created by Merck & Co. that is used to treat HIV infection. It was the first drug in its class, known as integrase inhibitors, to be approved by the U.S. Food and Drug Administration (FDA) in 2007.
Isentressis the brand name
Isentress Hd Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Isentress
Raltegravir
2007
20

Approved as Treatment by the FDA

Raltegravir, commonly known as Isentress, is approved by the FDA for 1 uses like HIV .
HIV
Used to treat Human Immunodeficiency Virus Type 1 (HIV-1) Infection in combination with null

Effectiveness

How Isentress Hd works in the bodyRaltegravir stops HIV from entering human cells. It does this by blocking a protein that HIV needs to get inside. Raltegravir is broken down in the body by a process called glucuronidation.

When to interrupt dosage

The suggested dosage of Isentress Hd is contingent upon the identified condition. The measure of dosage is subject to the specified technique of delivery, as featured in the table beneath.
Condition
Dosage
Administration
post-exposure prophylaxis for occupational exposure to HIV therapy
400.0 mg, , 300.0 mg, 25.0 mg, 100.0 mg, 600.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, Tablet - Oral, Granule, Granule - Oral
HIV
400.0 mg, , 300.0 mg, 25.0 mg, 100.0 mg, 600.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, chewable, Tablet, chewable - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, Tablet - Oral, Granule, Granule - Oral

Warnings

Isentress Hd Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
There are 20 known major drug interactions with Isentress Hd.
Common Isentress Hd Drug Interactions
Drug Name
Risk Level
Description
Atorvastatin
Minor
The risk or severity of myopathy and rhabdomyolysis can be increased when Raltegravir is combined with Atorvastatin.
Cerivastatin
Minor
The risk or severity of myopathy and rhabdomyolysis can be increased when Raltegravir is combined with Cerivastatin.
Fluvastatin
Minor
The risk or severity of myopathy and rhabdomyolysis can be increased when Raltegravir is combined with Fluvastatin.
Lovastatin
Minor
The risk or severity of myopathy and rhabdomyolysis can be increased when Raltegravir is combined with Lovastatin.
Mevastatin
Minor
The risk or severity of myopathy and rhabdomyolysis can be increased when Raltegravir is combined with Mevastatin.

Isentress Hd Novel Uses: Which Conditions Have a Clinical Trial Featuring Isentress Hd?

Currently, there are 43 active clinical trials assessing the potential of Isentress Hd to treat HIV (Human Immunodeficiency Virus).
Condition
Clinical Trials
Trial Phases
HIV
40 Actively Recruiting
Phase 2, Phase 3, Phase 1, Early Phase 1, Not Applicable, Phase 4
post-exposure prophylaxis for occupational exposure to HIV therapy
0 Actively Recruiting

Patient Q&A Section about isentress hd

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

When was ISENTRESS HD approved?

"was the date when the US Food and Drug Administration approved Isentress® HD, a new 1,200 mg once daily dosage form of raltegravir (an integrase strand transfer inhibitor)."

Answered by AI

What does HD stand for in ISENTRESS HD?

"ISENTRESS and ISENTRESS HD are drugs used to treat HIV-1 infection in adults when used in combination with other antiretroviral agents."

Answered by AI

Are Isentress and ISENTRESS HD interchangeable?

"Isentress 400 mg tablets are not the same as Isentress HD 600 mg tablets."

Answered by AI

What is the difference between Isentress and ISENTRESS HD?

"The medication Isentress HD is for adults and children who weigh at least 88 pounds (40 kg). The medication Isentress is for adults and children who weigh at least 4 pounds (2 kg). Both Isentress HD and Isentress can be taken without regard to food."

Answered by AI

Clinical Trials for Isentress Hd

Image of UCSF Zuckerberg San Francisco General Hospital in San Francisco, United States.

MucoCept-CVN for HIV Prevention

18 - 45
Female
San Francisco, CA
MucoCept-CVN uses a Lactobacillus strain native to the human vagina that is modified into a live biotherapeutic product (LBP) that continuously expresses a potent anti-HIV drug. If research shows that MucoCept-CVN is safe and effective, it could become a self-renewing, female-initiated prevention product for women that promotes vaginal health and provides protection from HIV. The goal of this first-in-human Phase 1 dose-ranging, randomized, placebo-controlled study of MucoCept-CVN is to collect data on safety, colonization, changes to the vaginal microbiota and clearance of the strain with antibiotics. Twelve healthy women will be enrolled and take either one or three doses of MucoCept-CVN or placebo, and a week later will receive antibiotics to clear the Lactobacillus strain. If research shows that MucoCept-CVN is safe and effective, it could become a self-renewing, long-acting, female-initiated prevention product for women that promotes vaginal health and provides protection from HIV.
Phase 1
Waitlist Available
UCSF Zuckerberg San Francisco General HospitalCraig Cohen, MD, MPHOsel, Inc.
Have you considered Isentress Hd clinical trials? We made a collection of clinical trials featuring Isentress Hd, we think they might fit your search criteria.Go to Trials
Image of Massachusetts General Hospital in Boston, United States.

SGLT2 Inhibitors for Metabolic Diseases

45 - 75
Female
Boston, MA
Women with HIV have an increased risk of having a myocardial infarction (heart attack) as compared to women without HIV. One of the mechanisms underlying the increased risk of myocardial infarction among women with HIV may involve reduced ability to increase blood flow through large and small coronary arteries at times when increased flow of oxygen-carrying blood is needed. We are conducting a study randomizing women with HIV and either diabetes, chronic kidney disease, or both to health education alone or to health education plus referral to see either an Endocrinologist or a Nephrologist in a subspecialty clinic for consideration of treatment with medication in a class known as sodium glucose transporter 2 (SGLT2) inhibitors. SGLT2 inhibitors are clinically approved for use in patients with diabetes or chronic kidney disease but have been shown to be underutilized in people with HIV. One of our key analytic aims will be to test if SGLT2 inhibitor therapy results in improved blood flow through the large and small coronary arteries among women with HIV and either diabetes, chronic kidney disease, or both but who have no history of myocardial infarction. A second aim will be to test if subspecialty clinic referral (with or without SGLT2 inhibitor therapy prescription) results in improved blood flow through the large and small coronary arteries among the same group.
Phase 2
Recruiting
Massachusetts General HospitalMarkella V Zanni, MD
Have you considered Isentress Hd clinical trials? We made a collection of clinical trials featuring Isentress Hd, we think they might fit your search criteria.Go to Trials
Image of Mills Clinical Research in West Hollywood, United States.

GS-1720 + GS-4182 for HIV

18+
All Sexes
West Hollywood, CA
The goal of this clinical study is to learn more about the experimental drugs GS-1720 (an oral, long-acting integrase strand transfer inhibitor (INSTI)) and GS-4182 (a prodrug of Lenacapavir (LEN)); to compare the combination of GS-1720 and GS-4182 with the current standard-of-care treatment bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) (Biktarvy), to see if the combination of GS-1720 and GS-4182 is safe and if it works for treating human immunodeficiency virus type 1 (HIV-1) infection in treatment-naive people with HIV-1 (PWH). This study has two phases: Phase 2 and Phase 3. The primary objectives of this study are: Phase 2: To evaluate the efficacy of oral weekly GS-1720 coadministered with GS-4182 versus continuing Biktarvy (BVY) in treatment-naive PWH at Week 24. Phase 3: To evaluate the efficacy of oral weekly GS-1720/GS-4182 fixed-dose combination (FDC) tablet regimen versus continuing BVY in treatment-naive PWH at Week 48.
Phase 2 & 3
Waitlist Available
Mills Clinical Research (+25 Sites)Gilead Study DirectorGilead Sciences
Image of Saskatchewan Health Authority in Regina, Canada.

DOVATO for HIV

18+
All Sexes
Regina, Canada
The goal of this clinical trial is to determine the efficacy of Dolutegravir/Lamivudine (DTG/3TC), or "Dovato", in virally-suppressed (HIV-1 RNA \< 200 copies/mL) individuals receiving opioid agonist therapy such as methadone, buprenorphine, slow-release morphine, after switching from their current suppressive antiretroviral therapy (ART). The main questions this trial seeks to answer are: 1. whether people living with HIV-1 (PLWH) on opioid agonist therapy (OAT) remain virally suppressed after switching to DTG/3TC from their current suppressive ART 48 weeks post-switch; 2. the number and type of adverse events (AEs) and serious adverse events (SAEs) attributable to DTG/3TC as documented per standard process at each study visit, and any discontinuations of DTG/3TC due to AEs and SAEs as determined by the study investigator; 3. the number of dosing changes in OAT attributable to DTG/3TC as determined by the study investigator and documented as per standard progress at each study visit; 4. the number of persons with any recreational or non-prescribed substances in their urine drug screens who remain virally suppressed (HIV-1 RNA \< 200 copies/mL) at 48 weeks post-switch from current suppressive ART to DTG/3TC; 5. any change from baseline values (i.e., day 0) to 48 weeks post-switch from current suppressive ART to DTG/3TC of serum creatinine and non-fasting lipid parameters; 6. any change from baseline value (i.e., day 0) to 48 weeks post-switch from current suppressive ART to DTG/3TC in HIV Treatment Satisfaction Questionnaire (Status) (HIVTSQs) scores; 7. the number of persons who remain virally suppressed (HIV RNA \< 200 copies/mL) at 48 weeks post-switch from current suppressive ART to DTG/3TC in conjunction with differing levels of adherence to DTG/3TC, and; 8. the number of persons who experience symptoms of opioid withdrawal or overdose per standardized survey or by self-report (e.g., overdose events) During the course of the study, participants will complete: * A set of questionnaires * Blood draws * A review of adverse events and concomitant medications * ECG scans at screening and 48 weeks * Urine drug screening * Physical exams * Review of alcohol consumption
Phase 4
Waitlist Available
Saskatchewan Health AuthorityViiV Healthcare
Image of University of Colorado - Anschutz Medical Campus in Aurora, United States.

Tesamorelin + Exercise for HIV

50 - 80
All Sexes
Aurora, CO
People with HIV experience earlier impairments in physical function compared to people in the general population. They also exhibit an earlier presentation and more rapid development of frailty, a multisystemic syndrome of aging characterized by reduced activity, fatigue, slowness, weakness, and weight loss. While exercise can improve physical function in people with HIV, it is less effective in doing so than in the general population and is difficult to sustain in the long-term. The goal of this clinical trial is to learn whether the medication tesamorelin will improve physical function and muscle health in adults with HIV when combined with exercise. Tesamorelin is a growth hormone-releasing hormone analogue that is FDA-approved to treat abdominal fat accumulation in people with HIV. While tesamorelin has also been shown to increase muscle mass and improve measures of muscle health, its effects on physical performance and muscle strength have not yet been evaluated. During a 24-week intervention phase, half of participants will be randomly assigned to receive tesamorelin and half of participants will be randomly assigned to receive placebo (a look-alike substance that contains no drug). All participants also will engage in a home-based exercise intervention supervised by an exercise coach. During a subsequent 24-week extension phase, individuals will be monitored off study drug and supervised exercise, and be encouraged to continue to exercise independently. The investigators will investigate effects of tesamorelin on physical function, muscle mass and quality, quality of life, and exercise adherence and self-efficacy. They also will evaluate whether effects of tesamorelin are maintained following treatment cessation. This study may identify an important strategy to improve how individuals aging with HIV function and feel with potential applications to other patient populations.
Phase 2
Recruiting
University of Colorado - Anschutz Medical Campus (+1 Sites)Kristine M. Erlandson, MD
Have you considered Isentress Hd clinical trials? We made a collection of clinical trials featuring Isentress Hd, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security